A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Primary Outcome Measures

1. Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1)
   Defined as the time between the randomization date and the date of progressive disease (PD) or death from any cause (whichever occurs first)
2. Overall Survival (OS)
   Defined as the time from the randomization date to the date of death from any cause

Secondary Outcome Measures

1. Objective Response (OR) as assessed by RECIST v1.1
2. Duration of Response (DOR) as assessed by RECIST v1.1
   Defined as the time between the date of the first documentation of objective tumor response (complete response (CR) or partial response (PR)) and the date of disease progression or to death from any cause (whichever occurs first)
3. Time to Objective Response (TTOR) as assessed by RECIST v1.1
   Defined as the time between randomization to the date of the first documentation of objective tumor response
4. Disease control as assessed by RECIST v1.1
   Defined as the best overall response (BOR) of confirmed CR, PR, or stable disease (SD)
5. PFS as assessed by RECIST v1.1